Upfront Chromatography Closes Investment Funding

DSM Venturing joins existing investors InnovationsKapital and NBGI Ventures in investment round

Upfront Chromatography A/S, the world's leading developer of customised industrial-scale protein chromatography processes, has announced that it has raised €6.8 million in investment funding. The investors in this round were DSM Venturing, the corporate venturing arm of Royal DSM N.V., and existing investors InnovationsKapital and NBGI Ventures.

Sales force to be strengthened 

Upfront will use the proceeds of the financing to significantly strengthen its sales force particularly in North America. In addition, it will be used to finance a programme to provide the world's first fully disposable chromatography system for biopharmaceutical production.

- As a major industrial group with significant involvement in pharmaceutical bioprocessing, DSM promises to be an excellent strategic fit for Upfront Chromatography and a very good complement to existing investors whose continued support demonstrates confidence in Upfront Chromatography and our strategic goal to become the leading provider of biopharmaceutical separation services, commented Anders Weber, CEO of Upfront Chromatography.

For further information visit the Upfront Chromatography homepage.

Source: Upfront Chromatography, press release, 24.09.2007